Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3881781 | 1.00 | GRM5 (0.42) | GRM5NR1H2USP2SMN1; SMN2ESR2 | |
| SCHEMBL3126731 | 0.86 | GRM5 (0.45) | GRM5NR1H2USP2SMN1; SMN2ESR2 | |
| SCHEMBL20658743 | 0.86 | GRM5 (0.45) | GRM5NR1H2USP2SMN1; SMN2ESR2 | |
| SCHEMBL3126738 | 0.86 | GRM5 (0.45) | GRM5NR1H2USP2SMN1; SMN2ESR2 | |
| SCHEMBL18281014 | 0.85 | ESR2 (0.37) | GRM5NR1H2USP2SMN1; SMN2ESR2 | |
| SCHEMBL18296909 | 0.85 | ESR2 (0.37) | GRM5NR1H2USP2SMN1; SMN2ESR2 | |
| SCHEMBL18281013 | 0.85 | ESR2 (0.37) | GRM5NR1H2USP2SMN1; SMN2ESR2 | |
| SCHEMBL29614642 | 0.85 | NR1H2 (0.41) | GRM5NR1H2USP2SMN1; SMN2ESR2 | |
| SCHEMBL29614722 | 0.85 | NR1H2 (0.41) | GRM5NR1H2USP2SMN1; SMN2ESR2 | |
| SCHEMBL29915399 | 0.83 | NR1H2 (0.42) | GRM5NR1H2USP2SMN1; SMN2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511144-B2 | Reverse hydroxamic acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| EP-1431285-B1 | REVERSE HYDROXAMIC ACID DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | STUDOR S.A. (LU) | 2004-12-02 | — | — | US | disclosed |
| EP-1431285-A1 | REVERSE HYDROXAMIC ACID DERIVATIVES | Kaken Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | TNF, RNASE1, IFNAR1 | GRM5 3136/4885NR1H2 214/4885USP2 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.